Sublethal engagement of apoptotic pathways in residual cancer
Shane T Killarney1, Stephen W G Tait2, Douglas R Green3
1Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.
Abstract:
Cytotoxic chemo-, radio-, and targeted therapies frequently elicit apoptotic cancer cell death. Mitochondrial outer membrane permeabilization (MOMP) is a critical, regulated step in this apoptotic pathway. The residual cancer cells that survive treatment serve as the seeds of eventual relapse and are often functionally characterized by their transient tolerance of multiple therapeutic treatments. New studies suggest that, in these cells, a sublethal degree of MOMP, reflective of incomplete apoptotic commitment, is widely observed. Here, we review recent evidence that this sublethal MOMP drives the aggressive features of residual cancer cells while templating a host of unique vulnerabilities, highlighting how failed apoptosis may counterintuitively enable new therapeutic strategies to target residual disease (RD).
Insights
Sublethal mitochondrial outer membrane permeabilization (MOMP) in residual cancer cells drives relapse. Understanding this failed apoptosis reveals unique vulnerabilities for targeting aggressive cancer cells and residual disease (RD).
Area of Science:
- Oncology
- Cell Biology
- Cancer Therapeutics
Background:
- Cancer therapies like chemotherapy, radiation, and targeted treatments induce apoptosis, a programmed cell death pathway.
- Mitochondrial outer membrane permeabilization (MOMP) is a crucial, regulated step in apoptosis.
- Residual cancer cells surviving treatment often exhibit tolerance and are implicated in relapse.
Purpose of the Study:
- To review evidence linking sublethal MOMP in residual cancer cells to aggressive features.
- To explore how incomplete apoptotic commitment in these cells creates unique therapeutic vulnerabilities.
- To highlight novel strategies for targeting residual disease (RD) by exploiting failed apoptosis.
Main Methods:
- Review of recent scientific literature and evidence.
- Analysis of the role of sublethal MOMP in cancer cell survival and aggressiveness.
- Exploration of therapeutic implications of failed apoptosis in residual cancer.
Main Results:
- Sublethal MOMP is widely observed in residual cancer cells that survive therapy.
- This incomplete apoptotic process contributes to the aggressive phenotype of these cells.
- Failed apoptosis in residual disease (RD) presents exploitable vulnerabilities.
Conclusions:
- Sublethal MOMP is a key driver of aggressive residual cancer cell characteristics.
- Understanding the mechanisms of failed apoptosis offers new therapeutic avenues for residual disease (RD).
- Targeting vulnerabilities arising from incomplete apoptosis may improve cancer treatment outcomes.
Related Concept Videos
01:17The Extrinsic Apoptotic Pathway
01:31The Intrinsic Apoptotic Pathway
01:30Apoptosis
01:17Phagocytosis of Apoptotic Cells
Normal cells contain receptors that prevent them from being recognized...
01:30Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...